Dexiang Ji

Nanchang, 330006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Phosphorylation of USP32 by CDK5 regulates Rap1 stability and therapeutic resistance in pancreatic ductal adenocarcinoma.

Phosphorylation of USP32 by CDK5 regulates Rap1 stability and therapeutic resistance in pancreatic ductal adenocarcinoma.

Journal: Oncogene

Published: September 05, 2024

Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1/Th2 balance and alleviates immune thrombocytopenia in pregnancy.

Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1/Th2 balance and alleviates immune thrombocytopenia in pregnancy.

Journal: Human cell

Published: July 05, 2024

Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia.

Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia.

Journal: International journal of general medicine

Published: May 17, 2024

Author Correction: Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.

Author Correction: Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.

Journal: Scientific reports

Published: November 30, 2023

Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.

Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.

Journal: The Lancet. Haematology

Published: November 07, 2022

A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature.

A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature.

Journal: Aging

Published: October 08, 2022

Functional deficiency of bone marrow mesenchymal stem cells in patients with immune thrombocytopenia: An update

Functional deficiency of bone marrow mesenchymal stem cells in patients with immune thrombocytopenia: An update

Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Published: April 02, 2022

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion.

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion.

Journal: The Journal of international medical research

Published: December 17, 2021

The Mechanistic Effects and Clinical Applications of Various Derived Mesenchymal Stem Cells in Immune Thrombocytopenia.

The Mechanistic Effects and Clinical Applications of Various Derived Mesenchymal Stem Cells in Immune Thrombocytopenia.

Journal: Acta haematologica

Published: February 02, 2021

Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis.

Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis.

Journal: Human cell

Published: November 23, 2020

Small-sized extracellular vesicles (EVs) derived from acute myeloid leukemia bone marrow mesenchymal stem cells transfer miR-26a-5p to promote acute myeloid leukemia cell proliferation, migration, and invasion.

Small-sized extracellular vesicles (EVs) derived from acute myeloid leukemia bone marrow mesenchymal stem cells transfer miR-26a-5p to promote acute myeloid leukemia cell proliferation, migration, and invasion.

Journal: Human cell

Published: November 23, 2020

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.

Journal: Translational cancer research

Published: October 22, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026